Free Trial
NASDAQ:CALC

CalciMedica 8/12/2025 Earnings Report

CalciMedica logo
$2.37 -0.11 (-4.44%)
Closing price 08/13/2025 03:59 PM Eastern
Extended Trading
$2.53 +0.16 (+6.92%)
As of 08/13/2025 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CalciMedica EPS Results

Actual EPS
-$0.40
Consensus EPS
-$0.40
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

CalciMedica Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CalciMedica Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

CalciMedica Earnings Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd.
CalciMedica (CALC) Expected to Announce Earnings on Monday
See More CalciMedica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email.

About CalciMedica

CalciMedica (NASDAQ:CALC), Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

View CalciMedica Profile

More Earnings Resources from MarketBeat